Drug Trial Radar · NCT04823130
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Apr 22, 2021
Primary completion
Jun 30, 2022
Study completion Aug 30, 2022
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Mar 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: \- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: * Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus. * To evaluate the efficacy of dupilumab in AD participants with chronic pruritus. * To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.
Conditions
- Dermatitis Atopic
Interventions
Dupilumab (SAR231893)Drug
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17Time frame: Baseline, Week 17
- Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17Time frame: Baseline, Week 17
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number 8400001
Miami, Florida
Investigational Site Number 8400002
East Windsor, New Jersey
Investigational Site Number 2760001
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.